Chronic Kidney Disease – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises antihypertensive agents and SGLT-2 inhibitors, which are intended to delay disease progression. RAAS inhibitors are the standard-of-care therapy for CKD. SGLT-2 inhibitors are emerging to become another standard-of-care therapy for CKD treatment. In 2021 and 2023, AstraZeneca’s Farxiga and Eli Lilly’s Jardiance, respectively, received FDA approval for treatment of CKD regardless of diabetes status. Johnson & Johnson’s Invokana is approved for treatment of diabetic kidney disease, a major subpopulation of CKD patients. In 2021, Bayer’s Kerendia, a novel nonsteroidal selective mineralocorticoid receptor antagonist (MRA), was approved for treatment of diabetic kidney disease patients after it demonstrated significant cardioprotective and renoprotective benefits in the FIDELIO-DKD and FIGARO-DKD trials. This report provides insights on how the key drug classes for CKD treatment are used in newly diagnosed and recently treated CKD patients

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CKD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CKD patients?
  • How have Jardiance, Farxiga, and Kerendia been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of CKD patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of CKD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: AstraZeneca, Eli Lilly, Boehringer Ingelheim

Key drugs: Jardiance, Farxiga, Invokana, Kerendia

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

launch Related Market Assessment Reports